Rohan Garje, M.D., is a nationally renowned medical oncologist and the chief of genitourinary medical oncology at Miami Cancer Institute. Dr. Garje specializes in the treatment of prostate, kidney, bladder, testicular and penile cancer. Dr Garje has significant expertise in the design of novel investigator-initiated clinical trials and has served as the principal investigator for numerous phase I, II and III clinical trials. He focuses on providing precision oncology care utilizing targeted therapy, hormonal therapy, immunotherapy, radioligand therapy and chemotherapy. Dr. Garje is an internationally published leader in cancer research. He has amassed over 30 publications in prestigious journals, such as Journal of Clinical Oncology and the Journal of Immunotherapy for Cancer. At the Institute, he leads a team of medical oncologists actively involved in clinical research bringing industry-leading treatments to patients with genitourinary cancers. Before joining Miami Cancer Institute in 2022, Dr. Garje served as an associate professor of medicine in hematology and oncology at the University of Iowa/Holden Comprehensive Cancer Center.Dr. Garje is also the chair for the castration-resistant prostate cancer guidelines committee for the American Society of Clinical Oncology. He leads the committee’s work in reviewing research and writing guidelines for prostate cancer treatment. Dr. Garje serves on the editorial board for Current Problems in Cancer and is a reviewer for multiple journals including Journal of Clinical Oncology and Journal of Oncology Practice. Dr. Garje is passionate about providing individual care to each patient because each has a unique journey. He takes time to listen to patients and walks with them throughout their treatment. When he is not treating patients, Dr. Garje enjoys spending time with his family and traveling, always with a camera in hand. He is fluent in English, Hindi, Telugu and Marathi.